aspirin has been researched along with Placental Abruption in 21 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia." | 9.07 | Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991) |
| "Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration." | 9.05 | Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020) |
| "We aimed to estimate the effect of aspirin on the risk of placental abruption or antepartum hemorrhage in relation to gestational age at onset of therapy and the dosage of the drug." | 8.98 | Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. ( Bujold, E; Nicolaides, KH; Roberge, S, 2018) |
| "To perform a meta-analysis determining the association of low-dose aspirin treatment with subsequent abruptio placentae or perinatal mortality." | 8.79 | Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality. ( Cliver, SP; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995) |
| "To evaluate the effects of low-molecular-weight heparin (LMWH) combined with low-dose aspirin (LDA) in pregnant women with a history of pregnancy-related hypertensive disorders." | 8.02 | Effects of low-molecular-weight heparin and aspirin in recurrent pre-eclampsia: A stratified cohort study. ( Chen, Y; Shen, F; Wang, J; Yang, W; Zhang, Y; Zhou, J, 2021) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 7.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "The incidence of preeclampsia was lower in the aspirin group (69 of 1485 women [4." | 6.67 | Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, SN; Klebanoff, M; McNellis, D; Paul, RH; Rocco, L; Romero, R; Rosen, M; Sibai, BM; Thom, E; Witter, F, 1993) |
| "A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia." | 5.07 | Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991) |
| "To perform a meta-analysis and meta-regression of randomized controlled trials (RCTs) to evaluate the impact of low-dose aspirin (LDA) on perinatal outcome, independent of its effect on pre-eclampsia (PE), preterm birth and low birth weight." | 5.05 | Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression. ( Hartel, G; Kumar, S; Robertson, NT; Turner, JM, 2020) |
| "Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration." | 5.05 | Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020) |
| "We aimed to estimate the effect of aspirin on the risk of placental abruption or antepartum hemorrhage in relation to gestational age at onset of therapy and the dosage of the drug." | 4.98 | Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. ( Bujold, E; Nicolaides, KH; Roberge, S, 2018) |
| "To perform a meta-analysis determining the association of low-dose aspirin treatment with subsequent abruptio placentae or perinatal mortality." | 4.79 | Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality. ( Cliver, SP; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995) |
| "A retrospective study of 32 women with severe recurrent placenta-mediated complications (preeclampsia with severe features, placental abruption, severe intrauterine growth retardation or intra uterine fetal death) in spite of treatment with low molecular weight heparin and low dose aspirin in previous pregnancy." | 4.12 | Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study. ( Asher-Landsberg, J; Gamzu, R; Kliger, C; Kupferminc, MJ; Rimon, E; Skornick-Rapaport, A; Yogev, Y, 2022) |
| "To evaluate the effects of low-molecular-weight heparin (LMWH) combined with low-dose aspirin (LDA) in pregnant women with a history of pregnancy-related hypertensive disorders." | 4.02 | Effects of low-molecular-weight heparin and aspirin in recurrent pre-eclampsia: A stratified cohort study. ( Chen, Y; Shen, F; Wang, J; Yang, W; Zhang, Y; Zhou, J, 2021) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 3.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "The incidence of preeclampsia was lower in the aspirin group (69 of 1485 women [4." | 2.67 | Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, SN; Klebanoff, M; McNellis, D; Paul, RH; Rocco, L; Romero, R; Rosen, M; Sibai, BM; Thom, E; Witter, F, 1993) |
| "Placenta-mediated pregnancy complications are clinically important conditions and include preeclampsia, placental abruption, intrauterine growth restriction, and late fetal loss." | 2.66 | Understanding and Preventing Placenta-Mediated Pregnancy Complications. ( Blondon, M; Ní Áinle, F; Skeith, L, 2020) |
| "Preeclampsia, intrauterine growth restriction (IUGR), and placental abruption are obstetrical conditions that constitute the syndrome of ischemic placental disease or IPD, the leading cause of indicated preterm birth and an important cause of neonatal morbidity and mortality." | 2.50 | Prediction and prevention of ischemic placental disease. ( Cleary, KL; Friedman, AM, 2014) |
| "Recently, the thrombophilias have been revealed as risk factors for severe preeclampsia, abruptio placentae, fetal growth retardation, abortion and still birth as well." | 2.42 | [Anticoagulation and antiaggregation during pregnancy]. ( Biasiutti, FD; Strebel, JK, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 6 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Turner, JM | 1 |
| Robertson, NT | 1 |
| Hartel, G | 1 |
| Kumar, S | 1 |
| Theilen, LH | 1 |
| Campbell, HD | 1 |
| Mumford, SL | 1 |
| Purdue-Smithe, AC | 1 |
| Sjaarda, LA | 1 |
| Perkins, NJ | 1 |
| Radoc, JG | 1 |
| Silver, RM | 1 |
| Schisterman, EF | 1 |
| Ghazanfarpour, M | 1 |
| Sathyapalan, T | 1 |
| Banach, M | 1 |
| Jamialahmadi, T | 1 |
| Sahebkar, A | 1 |
| Skeith, L | 1 |
| Blondon, M | 1 |
| Ní Áinle, F | 1 |
| Zhang, Y | 1 |
| Shen, F | 1 |
| Yang, W | 1 |
| Wang, J | 1 |
| Zhou, J | 1 |
| Chen, Y | 1 |
| Kupferminc, MJ | 1 |
| Kliger, C | 1 |
| Rimon, E | 1 |
| Asher-Landsberg, J | 1 |
| Skornick-Rapaport, A | 1 |
| Gamzu, R | 1 |
| Yogev, Y | 1 |
| Roberge, S | 1 |
| Bujold, E | 1 |
| Nicolaides, KH | 1 |
| Bouvier, S | 1 |
| Chea, M | 1 |
| Ripart, S | 1 |
| Hanss, M | 1 |
| de Mazancourt, P | 1 |
| Gris, JC | 2 |
| Friedman, AM | 1 |
| Cleary, KL | 1 |
| Haddad, B | 2 |
| Winer, N | 1 |
| Chitrit, Y | 1 |
| Houfflin-Debarge, V | 1 |
| Chauleur, C | 1 |
| Bages, K | 1 |
| Tsatsaris, V | 1 |
| Benachi, A | 1 |
| Bretelle, F | 1 |
| Bastuji-Garin, S | 1 |
| Biasiutti, FD | 1 |
| Strebel, JK | 1 |
| Stone, S | 1 |
| Langford, K | 1 |
| Seed, PT | 1 |
| Khamashta, MA | 1 |
| Hunt, BJ | 1 |
| Poston, L | 1 |
| De Santis, M | 1 |
| Cavaliere, AF | 1 |
| Straface, G | 1 |
| Di Gianantonio, E | 1 |
| Caruso, A | 1 |
| Leduc, L | 1 |
| Dubois, E | 1 |
| Takser, L | 1 |
| Rey, E | 1 |
| David, M | 1 |
| Ylikorkala, O | 1 |
| Hauth, JC | 1 |
| Goldenberg, RL | 1 |
| Parker, CR | 1 |
| Cutter, GR | 1 |
| Cliver, SP | 1 |
| Sibai, BM | 3 |
| Caritis, SN | 1 |
| Thom, E | 1 |
| Klebanoff, M | 1 |
| McNellis, D | 1 |
| Rocco, L | 1 |
| Paul, RH | 1 |
| Romero, R | 1 |
| Witter, F | 1 |
| Rosen, M | 1 |
| Wright, CA | 1 |
| Tefferi, A | 1 |
| Sureau, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial[NCT00986765] | Phase 3 | 257 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-hypertensive Medication and Controls[NCT00759278] | 0 participants (Actual) | Observational | 2008-08-31 | Withdrawn (stopped due to No participants) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for aspirin and Placental Abruption
| Article | Year |
|---|---|
Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression.
Topics: Abruptio Placentae; Apgar Score; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retardation; Hum | 2020 |
Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses.
Topics: Abruptio Placentae; Aspirin; Female; Fetal Growth Retardation; Hemorrhage; Humans; Hypertension, Pre | 2020 |
Understanding and Preventing Placenta-Mediated Pregnancy Complications.
Topics: Abruptio Placentae; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; | 2020 |
Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage.
Topics: Abruptio Placentae; Aspirin; Female; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Pre-Eclamp | 2018 |
Prediction and prevention of ischemic placental disease.
Topics: Abruptio Placentae; Anticoagulants; Ascorbic Acid; Aspirin; Calcium, Dietary; Dietary Supplements; F | 2014 |
[Anticoagulation and antiaggregation during pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Abruptio Placentae; Administration, Oral; Adult; | 2003 |
Inherited and acquired thrombophilia: pregnancy outcome and treatment.
Topics: Abortion, Spontaneous; Abruptio Placentae; Anticoagulants; Aspirin; Female; Fetal Growth Retardation | 2006 |
Aspirin for the prevention of pre-eclampsia: where do we stand now?
Topics: Abruptio Placentae; Aspirin; Drug Evaluation; Female; Humans; Pre-Eclampsia; Pregnancy; Pregnancy Tr | 1995 |
Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality.
Topics: Abruptio Placentae; Aspirin; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Incidenc | 1995 |
Chronic hypertension in pregnancy.
Topics: Abruptio Placentae; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin | 1999 |
A single institutional experience with 43 pregnancies in essential thrombocythemia.
Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulf | 2001 |
Diagnosis and management of chronic hypertension in pregnancy.
Topics: Abruptio Placentae; Antihypertensive Agents; Aspirin; Blood Pressure Determination; Female; Humans; | 1991 |
3 trials available for aspirin and Placental Abruption
| Article | Year |
|---|---|
Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial.
Topics: Abruptio Placentae; Adult; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Humans; Pre-Eclam | 2016 |
Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
Topics: Abruptio Placentae; Adult; Aspirin; Double-Blind Method; Female; Humans; Hypertension; Incidence; Pa | 1993 |
Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group.
Topics: Abruptio Placentae; Aspirin; Birth Weight; Dipyridamole; Double-Blind Method; Drug Combinations; Fem | 1991 |
6 other studies available for aspirin and Placental Abruption
| Article | Year |
|---|---|
Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial.
Topics: Abruptio Placentae; Adult; Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnanc | 2020 |
Effects of low-molecular-weight heparin and aspirin in recurrent pre-eclampsia: A stratified cohort study.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Cohort Studies; Female; Gestational Age; Heparin | 2021 |
Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study.
Topics: Abruptio Placentae; Aspirin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans | 2022 |
Successful Pregnancy under Fibrinogen Substitution with Heparin and Aspirin in a Woman with Dysfibrinogenemia Revealed by Placental Abruption.
Topics: Abruptio Placentae; Afibrinogenemia; Aspirin; Cesarean Section; Consanguinity; Female; Fibrinogen; G | 2018 |
Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy.
Topics: Abortion, Spontaneous; Abruptio Placentae; Adult; Antiphospholipid Syndrome; Aspirin; Female; Fetal | 2003 |
Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Female; F | 2007 |